Site Map Press Room Careers
Financial
Quarterly Results
Financial Highlights
Annual Reports
Business Drivers
Investors
Contact Person
Frequently Asked Questions

Unaudited Quarterly Results for the First Quarter ended 30th June, 2003

(Rs.in Mio)
 

First Quarter Ended

Year ended

Particulars

 30.06.2003 30.06.2002 31.03.2003
  (Unaudited) (Unaudited) (Audited)
Net Sales/Income from Operations 3058.7 2472.4 11903.8
Other Income 56.4 31.8 240.5
Total Income 3115.1 2504.2 12144.3
Expenditure      
 a. (Increase) / Decrease in Stock in Trade (175.5) (66.2) (319.0)
 b. Consumption of Raw Materials 2070.0 1622.1 7547.7
 c. Staff Cost 111.5 58.9 335.2
 d. Other Expenditure 658.9 520.2 2521.8
Total expenditure 2664.9 2135.0 10085.7
Profit Before Depreciation, Interest & Tax 450.2 369.2 2058.6
Interest 60.0 128.0 425.9
Depreciation 70.7 39.3 231.8
Profit before taxation 319.5 201.9 1400.9
Provision for Taxation      
a. Current Tax 69.9 45.0 253.0
b. Deferred Tax 19.1 6.0 112.1
c. Tax adjustments of previous years      
Net Profit 230.5 150.9 1031.4
Paid-up Equity Share Capital  232.5 222.0 232.5
(Face value Rs. 10 per share)      
Reserves excluding Revaluation Reserves - - 5101.4
Basic Earnings per Share (in Rs.) (not annualised) 9.91 6.86 45.46
Diluted Earnings per share (Rs.) 9.87 6.86 45.46
Aggregate of Non-promoters Shareholding      
a. Number of Shares 8978473 7963498 8930473
b. Percentage of Shareholding 38.62 35.87 38.41

Segment wise Revenue, Results and Capital employed

(Rs.in Mio)
  First Quarter Ended Year ended

Particulars

 30.06.2003 30.06.2002 31.03.2003
  (Unaudited) (Unaudited) (Audited)
1. Segment Revenue      
a. Bulk Drugs & Drug Intermediaries 3005.2 2423.2 12179.1
b. Formulation 119.7 143.2 642.5
c. Research & Development - - -
Total 3124.9 2566.4 12821.6
Less: Inter segment revenue 58.2 79.9 859.3
Net Sales/Income from operation 3066.7 2486.5 11962.3
2. Segment Results Profit(+) / Loss(-) before tax and interest      
a. Bulk Drugs & Drug Intermidiaries 428.5 362.2 1852.3
b. Formulations 14.7 11.2 97.1
c. Research & Development (41.7) (18.9) (129.4)
Total 401.5 354.5 1820.0
Less: (i) Interest (Net) 50.6 120.8 381.8
   (ii) Other un-allocable expenditure 31.4 31.8 37.3
  net of unallocable income      
Total Profit before tax 319.5 201.9 1400.9
3. Capital Employed      
a. Bulk Drugs 7803.4 4189.3 7331.6
b. Formulation 1421.8 1190.8 1463.3
c. Research & Development 271.8 179.7 256.1
Total 9497.0 5559.8 9051.0
Notes:
1. The above unaudited results were taken on record by the Board at its meeting held on 31.07.2003.
2. During the quarter, the total number of investors complaints received were 67 and all of them were resolved and no complaint is pending at the end of the quarter.
3. Figures for the previous quarter have been rearranged wherever necessary.
For and on behalf of the Board
Sd/-
Place: Hyderabad K.Nityananda Reddy
Date : 31.07.2003 Managing Director
Site Map Press Room Careers